FDA가 국소 진행성 절제 불가능 NSCLC 환자를 위한 오시머티닙 사용을 승인했다.
FDAは、局所進行性切除不能NSCLC患者に対するオシメルチニブの使用を承認した。
The FDA has approved the use of osimertinib, a third-generation EGFR tyrosine kinase inhibitor, for the treatment of locally advanced, unresectable non-small cell lung cancer in certain adult patients.
유방암 치료 비용은 환자의 생존율이나 질병 악화와 관련이 없다.
胃食道がんの治療において、PD-L1発現状況やCLDN18.2などの新しいバイオマーカーを活用し、FLOT療法やFOLFIRINOX療法などの新しい化学療法レジメンを組み合わせることで、より効果的な治療アプローチが期待できる。
The monthly cost of treating breast cancer is not associated with improved overall survival or progression-free survival for patients.
Oncologists are exploring new biomarker-driven approaches, combination therapies, and sequencing strategies to improve outcomes for patients with esophageal and gastric cancers.
Immunotherapy combined with chemotherapy has significantly improved outcomes for patients with advanced or recurrent endometrial cancer, offering substantial survival benefits across different molecular subtypes.
Black women in the United States have higher breast cancer mortality rates than White women across all tumor subtypes, with the greatest disparity observed in hormone receptor-positive (HR+), human epidermal growth factor 2–negative (HER2−) tumors.
접합 항체는 난소암 치료에 있어 중요한 새로운 치료법으로 부상하고 있다. 이러한 분자는 암세포를 직접 표적화하여 세포독성 치료제를 전달함으로써 치료 효과를 높이고 부작용을 줄일 수 있다.